This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grunder, G. Articles by Drewe, J. Search for Related Content PubMed PubMed Citation Articles by Grunder, G. Articles by Drewe, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2006, p. 68-72, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.68-72.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Lack of Pharmacokinetic Interaction between Linezolid and Antacid in Healthy Volunteers

Gabriela Grunder,¹ Yvonne Zysset-Aschmann,¹ Florence Vollenweider,¹ Thomas Maier,² Stephan Krähenbühl,¹ and Juergen Drewe^1*

Department of Clinical Pharmacology and Toxicology and Research, University Clinic Basel, Basel, Switzerland,¹ Pfizer Pharmaceuticals, Zürich, Switzerland²

Received 19 July 2005/ Returned for modification 4 September 2005/ Accepted 1 October 2005

Several antibiotics show significant pharmacokinetic interactions when they are given orally concomitantly with antacids. The objective of this study was to evaluate the effects of antacid (containing magnesium) on the pharmacokinetics of linezolid. A single dose of 600 mg linezolid was given orally alone and 10 min after administration of the antacid Maalox 70mVal, which contains 600 mg magnesium hydroxide and 900 mg aluminum hydroxide, to nine healthy males and nine healthy females in a crossover and randomized study. Linezolid plasma concentrations were determined by high-performance liquid chromatography, and pharmacokinetic parameters were calculated for both treatments. Coadministration with antacids did not change the pharmacokinetics of linezolid. The ratios (90% confidence intervals) of the individual values of the area under the concentration-time curve and the maximum concentration in plasma (C_max) (linezolid plus antacid versus linezolid alone) were 1.01 (0.99 to 1.02) and 0.99 (0.96 to 1.02), respectively. Likewise, no significant difference in any of the other pharmacokinetic parameters was observed between the treatment groups (the time to C_max, lag time, volume of distribution [V/F], and clearance [CL/F]). However, a significant sex difference was observed for AUC, C_max, V/F, and CL/F; and these differences could be almost completely explained by the differences in body weight between males and females. No clinically relevant adverse effects were detected under either condition. The coadministration of antacids had no effect on the pharmacokinetics of linezolid. This demonstrates that the oral absorption of linezolid was not affected by the presence of antacids containing magnesium hydroxide and aluminum hydroxide. Antacids can be safely administered together with linezolid.

---

* Corresponding author. Mailing address: University Clinic Basel, Department of Clinical Pharmacology and Toxicology, Petersgraben 4, CH-4031 Basel, Switzerland. Phone: 41-61 265 38 48. Fax: 41-61 265 85 81. E-mail: juergen.drewe{at}unibas.ch.

---

Antimicrobial Agents and Chemotherapy, January 2006, p. 68-72, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.68-72.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Nassr, N., Lahu, G., Hunnemeyer, A., von Richter, O., Knoerzer, D., Reutter, F., Zech, K., Hermann, R. (2007). Magnesium Hydroxide/Aluminium Hydroxide-Containing Antacid Does Not Affect the Pharmacokinetics of the Targeted Phosphodiesterase 4 Inhibitor Roflumilast. J Clin Pharmacol 47: 660-666 [Full Text]